



PEAKSTONE

Healthcare Industry M&A and Valuation Insights

February 2022

www.peakstone.com

Overview

PEAKSTONE

2008

Year Founded

500+

Transactions by Peakstone MDs

\$200+ Billion

Capital Raised by Peakstone MDs

25+ Years

Average Years of Peakstone MD Experience

40+

Investment Banking Professionals

18+

Industries Covered

\$10 - \$500 Million

Client Revenue Profile

30+ Countries

Global Reach

Selected Transactions

<p>Healthcare Equipment Rental Business</p>  <p>M&A Advisor PEAKSTONE</p>	<p>KIRKPATRICK DENTAL CARE</p>  <p>M&A Advisor PEAKSTONE</p>	<p>ENTEGRA CAPITAL</p> <p>ADELPHI CAPITAL</p> <p>M&A Advisor PEAKSTONE</p>	<p>LG Medical Technologies, Inc.</p>  <p>M&A Advisor PEAKSTONE</p>	<p>PRECISION SPINE</p>  <p>M&A Advisor PEAKSTONE</p>	<p>INTEGRATIVE PET CARE</p> <p>Private Investor Group</p> <p>M&A Advisor PEAKSTONE</p>
<p>Healthcare Advance Funding</p>  <p>M&A Advisor PEAKSTONE</p>	 <p>M&A Advisor PEAKSTONE</p>	<p>examinetics <small>InsightXentia</small></p> <p>Shareholder Recap</p> <p>M&A Advisor PEAKSTONE</p>	<p>Medical Necessities</p> <p>Private Investor Group</p> <p>M&A Advisor PEAKSTONE</p>	 <p>HealthLOGIC</p>  <p>M&A Advisor PEAKSTONE</p>	<p>medex <small>Johnson & Johnson</small></p> <p>One Equity Partners</p> <p>M&A Advisor</p>

Contact Information



Alex Fridman – Managing Partner

(312) 346-7303

afridman@peakstone.com



Stephen Sleigh – Managing Partner

(312) 346-7318

ssleigh@peakstone.com



Jeff Temple – Managing Partner

(312) 346-7301

jtemple@peakstone.com



Ethan White – Associate

(312) 346-7307

ewhite@peakstone.com



Noah Robles – Analyst


(312) 346-7349

nrobles@peakstone.com


U.S. M&A Activity

PEAKSTONE

Healthcare M&A Count Across the U.S. (2000 – 2021)



U.S. Healthcare M&A Count (2000 – 2021)




Source: Capital IQ
 Note: As of Dec 31, 2021


Transaction Analysis

PEAKSTONE

Median Transaction Value (2000 – 2021)




Median EV Multiples (2000 – 2021)




Source: Capital IQ
 Note: As of Dec 31, 2021

Relative Stock Performance (2012 – 2021)



EV/EBITDA Trend (2012 – 2021)



Key

— Healthcare Providers Index (“Providers”)	— Life Sciences Tools & Pharma Index (“Life Sciences”)
— Healthcare Equipment & Tech Index (“HealthTech”)	— S&P 500
— Biotechnology Index (“Biotech”)	

Peakstone Healthcare Providers Index: UNH, CVS, ANTM, HCA, CI, HUM, CNC, MCK, CAH, UHS, CHE, EHC, AMN, AMEH, CVET, SGFY, MD
Peakstone Healthcare Equipment & Tech Index: ABT, SYK, EW, BDX, BSX, DXCM, ALGN, BAX, VEEV, RMD, CERN, ZBH, DOCS, OMCL, GMED, CNMD, NUVA, VCRA, MDRX
Peakstone Biotechnology Index: ABBV, AMGN, MRNA, GILD, REGN, VRTX, BIIB, BMRN, DNA, NVAX, UTHR
Peakstone Life Sciences Tools & Pharma Index: JNJ, PFE, TMO, LLY, DHR, MRK, BMY, ILMN, IQV, A, AVTR, PKI, BIO, WAT, CTLT, TECH, CRL, RPRX, VTRS, SYNH, MEDP, OGN, NEO, PCRX, HRMY, CTKB

Source: Capital IQ

Note: As of Dec 31, 2021

Selected Transactions

PEAKSTONE

Date	Target	Buyer	Deal Size (\$mm)	Target Description	Transaction Comments
Dec-2021	Experimur	Frontage Laboratories	\$72	Experimur provides toxicology testing and laboratory services for biopharmaceutical companies	Frontage Laboratories agreed to acquire Experimur for \$72 million on December 29, 2021.
Dec-2021	Hydrofera	Essity	\$131	Hydrofera develops and manufactures Polyvinyl Alcohol (PVA) foam products for medical applications	Essity (OM:ESSITY B) acquired Hydrofera for ~\$130 million on December 29, 2021. The purchase price is \$116 million with a potential additional earnout of \$15 million on a cash and debt free basis.
Dec-2021	Concentra Group Holdings	Select Medical Corporation	\$626	Concentra Group Holdings provides occupational medicine and urgent care services	Select Medical Corporation acquired an additional ~20.23% stake in Concentra Group Holdings for ~\$630 million on December 24, 2021.
Dec-2021	Ortho Clinical Diagnostics	Quidel Corporation	\$8,424	Ortho Clinical Diagnostics engages in the vitro diagnostics business	Quidel Corporation entered into a definitive agreement to acquire Ortho Clinical Diagnostics for \$5.9 billion on December 22, 2021. Ortho shareholders will receive \$7.14 in cash per common share and 0.1055 shares of common stock in the combined company for each Ortho common share held.
Dec-2021	Personal Genome Diagnostics	Laboratory Corporation of America Holdings	\$575	Personal Genome Diagnostics engages in the patient-specific analyses of cancer genomes using digital characterization and monitoring technologies	Laboratory Corporation of America entered into a definitive agreement to acquire Personal Genome Diagnostics for \$580 million on December 23, 2021. Labcorp will pay \$450 million in cash at closing and up to an additional \$125 million on achieving future performance milestones.
Dec-2021	DAS Medical Holdings	UFP Technologies	\$95	DAS Medical Holdings designs and manufactures surgical equipment covers, robotic draping systems, and fluid control pouches	UFP Technologies (NasdaqCM:UFPT) acquired Das Medical for \$95 million on December 22, 2021. UFP Technologies paid \$75 million in cash and cash amount may be increased by up to \$20 million in earn-out payments based upon the performance of the business.
Dec-2021	Talis Clinical	Getinge	\$65	Talis Clinical develops cloud-based software solutions to support patient care that impact clinicians and healthcare organizations	Getinge (OM:GETI B) acquired Talis Clinical for ~SEK 600 million on December 23, 2021. Getinge has paid SEK 596 million for 100% of the equity interest in Talis Clinical LLC on a debt-free basis and subject to working capital adjustments.
Dec-2021	Scanning Technology business of Carestream Dental	Envista Holdings Corporation	\$600	Scanning Technology business of Carestream Dental comprises of Intra-Oral Scanner business	Envista Holdings Corporation (NYSE:NVST) entered into an agreement to acquire Scanning Technology business of Carestream Dental for \$600 million on December 22, 2021.
Dec-2021	Amunix Pharmaceuticals	Sanofi	\$1,225	Amunix Pharmaceuticals discovers and develops protein and peptide therapeutics products for cancer	Sanofi entered into an agreement to acquire Amunix Pharmaceuticals for ~\$1.2 billion from a group of seller on December 21, 2021.
Dec-2021	Senti Biosciences	Dynamics Special Purpose Corp.	\$260	Senti Biosciences engages in research and development of synthetic biotechnology for the treatment of cancer	Dynamics Special Purpose (NasdaqCM:DYNS) entered into a definitive business combination agreement to acquire Senti Biosciences for ~\$260 million on December 19, 2021.